UPDATE: Cowen Starts Absci Corp. (ABSI) at Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ABSI Hot Sheet
Rating Summary:
14 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Cowen analyst Doug Schenkel initiates coverage on Absci Corp. (NASDAQ: ABSI) with a Market Perform rating.
The analyst comments "We are enthused about ABSI's drug creation platform and the potential for meaningful revenue growth as a potentially important enabler in a large and growing biopharma product category. That said, the risk/reward seems balanced at current levels pending more details on partners and platform specs, and more validating milestones."
For an analyst ratings summary and ratings history on Absci Corp. click here. For more ratings news on Absci Corp. click here.
Shares of Absci Corp. closed at $25.01 yesterday.
You May Also Be Interested In
- Insulet Corporation (PODD) PT Raised to $163 at TD Cowen
- Camtek (CAMT) PT Lowered to $140 at Stifel
- Livanova (LIVN) PT Raised to $115 at Mizuho
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
